HomeREGULATORY
REGULATORY

Japan’s 1st Herceptin Biosimilar Clears MHLW Panel, Now in Line for March Approval for Gastric Cancer
(Feb.5.2018)

Japan’s first Herceptin (trastuzumab) biosimilar cleared a key health ministry panel for the treatment of gastric cancer on February 2, putting it in line for an official stamp of approval in March and listing in May if all goes without a hitch ...
(LOG IN FOR FULL STORY)

News Calendar